UBS Group
MRVI icon

UBS Group’s Maravai LifeSciences MRVI Stock Holding History

UBS Group’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$543K Sell
191,798
-547,129
-74% -$1.85M ﹤0.01% 6020
2025
Q4 		$2.4M Sell
738,927
-1,660,285
-69% -$5.59M ﹤0.01% 4804
2025
Q3 		$6.89M Sell
2,399,212
-833,072
-26% -$2.13M ﹤0.01% 3696
2025
Q2 		$7.79M Buy
3,232,284
+2,676,831
+482% +$5.63M ﹤0.01% 3377
2025
Q1 		$1.23M Sell
555,453
-1,395,690
-72% -$5.52M ﹤0.01% 5105
2024
Q4 		$10.6M Buy
1,951,143
+1,717,771
+736% +$11.1M ﹤0.01% 2972
2024
Q3 		$1.94M Buy
233,372
+66,349
+40% +$574K ﹤0.01% 4024
2024
Q2 		$1.2M Buy
167,023
+76,955
+85% +$664K ﹤0.01% 4240
2024
Q1 		$781K Sell
90,068
-63,425
-41% -$429K ﹤0.01% 4807
2023
Q4 		$1.01M Buy
153,493
+96,217
+168% +$622K ﹤0.01% 4499
2023
Q3 		$573K Sell
57,276
-84,192
-60% -$924K ﹤0.01% 4554
2023
Q2 		$1.76M Buy
141,468
+27,624
+24% +$373K ﹤0.01% 3660
2023
Q1 		$1.59M Buy
113,844
+23,150
+26% +$332K ﹤0.01% 3667
2022
Q4 		$1.3M Buy
90,694
+6,736
+8% +$106K ﹤0.01% 3826
2022
Q3 		$2.14M Sell
83,958
-9,171
-10% -$230K ﹤0.01% 3100
2022
Q2 		$2.65M Sell
93,129
-8,201
-8% -$260K ﹤0.01% 2906
2022
Q1 		$3.57M Sell
101,330
-20,302
-17% -$681K ﹤0.01% 2882
2021
Q4 		$5.1M Sell
121,632
-17,554
-13% -$711K ﹤0.01% 2792
2021
Q3 		$6.83M Sell
139,186
-11,481
-8% -$560K ﹤0.01% 2357
2021
Q2 		$6.29M Buy
150,667
+80,369
+114% +$3.11M ﹤0.01% 2454
2021
Q1 		$2.5M Buy
70,298
+34,423
+96% +$1.14M ﹤0.01% 3334
2020
Q4 		$1.01M Buy
+35,875
New +$999K ﹤0.01% 4025

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's MRVI Position: Q1 2026 in Review

UBS Group reduced its Maravai LifeSciences (MRVI) stake by 74% in Q1 2026, selling an estimated $1.85M and leaving 191,798 shares worth $543K. The position accounts for ﹤0.01% of the portfolio, ranked #6020.

UBS Group first reported a position in MRVI in Q4 2020 and has held it in 22 quarters since. The position peaked at $10.6M in Q4 2024. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • UBS Group held 191,798 shares of Maravai LifeSciences worth $543K as of Q1 2026.
  • UBS Group sold 547,129 Maravai LifeSciences shares in Q1 2026, an estimated $1.85M.
  • Maravai LifeSciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6020 holding.
  • UBS Group first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 22 quarters since.
  • UBS Group's Maravai LifeSciences position peaked at $10.6M in Q4 2024.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.